|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500114968 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-19 15:21:37 |
|
注册时间: Date of Registration: |
2025-12-19 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
无偿献血全血间隔期调整:一项多中心、回顾性研究 |
|
Public title: |
Adjustment of the Whole blood donation Intervals in China: A Multicenter, Retrospective Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
全血间隔期小于6个月对献血安全性、献血行为及既往血液供应的研究 |
|
Scientific title: |
A Study on the Blood Donation Interval of Less Than 6 Months Regarding Donor Safety, Donation Behavior, and Historical Blood Supply |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
胡雨薇 |
研究负责人: |
刘忠 |
|
Applicant: |
Hu Yuwei |
Study leader: |
Liu Zhong |
|
申请注册联系人电话: Applicant telephone: |
+86 28 6164 8562 |
研究负责人电话:
Study leader's |
+86 28 6164 8562 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
249468856@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
liuz@ibt.pumc.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国四川省成都市成华区华彩路26号 |
研究负责人通讯地址: |
中国四川省成都市成华区华彩路26号 |
|
Applicant address: |
26 Huacai Rd, Longtan Industry Zone Chenghua District, Chengdu, Sichuan, China |
Study leader's address: |
26 Huacai Rd, Longtan Industry Zone Chenghua District, Chengdu, Sichuan, China |
|
申请注册联系人邮政编码: Applicant postcode: |
610052 |
研究负责人邮政编码: Study leader's postcode: |
610052 |
|
申请人所在单位: |
中国医学科学院输血研究所 |
||
|
Applicant's institution: |
Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Blood Transfusion |
||
|
研究负责人所在单位: |
中国医学科学院输血研究所 |
||
|
Affiliation of the Leader: |
Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Blood Transfusion |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025011 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国医学科学院输血研究所伦理审查委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Institute of Blood Transfusion, Chinese Academy of Medical Sciences |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-11-10 00:00:00 | ||
|
伦理委员会联系人: |
陈勇军 |
||
|
Contact Name of the ethic committee: |
Chen Yongjun |
||
|
伦理委员会联系地址: |
中国四川省成都市成华区华彩路26号 |
||
|
Contact Address of the ethic committee: |
26 Huacai Rd, Longtan Industry Zone Chenghua District, Chengdu, Sichuan, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 28 8334 0579 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
中国医学科学院输血研究所 |
||||||||||||||||||||||
|
Primary sponsor: |
Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Blood Transfusion |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国四川省成都市成华区华彩路26号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
26 Huacai Rd, Longtan Industry Zone Chenghua District, Chengdu, Sichuan, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
中国医学科学院医学与健康科技创新工程(2021-I2M-1-060),血液安全预警体系构建及干预研究(2021-I2M-1-060-2024-C0) |
||||||||||||||||||||||
|
Source(s) of funding: |
Medical and Health Science and Technology Innovation Project of the Chinese Academy of Medical Sciences (2021-I2M-1-060), Blood hemovigilance System Construction and Intervention Research (2021-I2M-1-060-2024-C0) |
||||||||||||||||||||||
|
研究疾病: |
健康者献血 |
||||||||||||||||||||||
|
Target disease: |
Blood donation |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
主要目的: 评估献全血间隔期≥3个月,且<6个月的人群献血的安全性。 次要目的: 探索献全血间隔期≥3个月,且<6个月的人群的献血行为变化以及其对血液供应的潜在影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary objective: To evaluate the safety of whole blood donation among individuals with donation intervals ≥3 months and <6 months. Secondary objective: To explore changes in donation behavior and the potential impact on blood supply among individuals with whole blood donation intervals ≥3 months and <6 months. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1) 年龄 ≥18 岁且 ≤65 岁; (2) 献血时间:2018年1月1日至2024年12月31日(深圳经济特区)、2012年3月1日至2025年5月1日(海南经济特区)。 (3) 满足献血合格标准; |
||||||||||||||||||||||
|
Inclusion criteria |
(1) Aged >= 18 years and <= 65 years; (2) Blood donation period: November 1, 1995 to January 1, 2025 (Shenzhen Special Economic Zone), and May 1, 2019 to May 1, 2025 (Hainan Special Economic Zone); (3) Meeting the eligibility criteria for blood donation; |
||||||||||||||||||||||
|
排除标准: |
(1) 研究者判定数据不完整或不合规者。 (2) 献血类型非全血。 (2)献血次数仅1次。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Those whose data are determined by the researchers to be incomplete or non-compliant. (2) Blood donation type: whole blood. (3) Only one Blood donation |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-11-10 00:00:00至 To 2026-04-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-12-22 00:00:00 至 To 2026-02-22 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
None |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |